Form 10-Q · Quarterly report
Dexcom 10-Q, filed Jul 30, 2026
- Filed
- CIK
- 0001093557
- Accession no.
- 0001093557-26-000143
Summary
Dexcom reported second-quarter 2026 revenue of $1.31 billion, up 13% from the same period in 2025, with net income of $249.1 million, up 39%, and operating income of $318.3 million, up 50%. The company attributed the revenue increase mainly to higher disposable sensor volumes and favorable revenue per customer, partly offset by channel and product mix and rebate eligibility.
Key points
- Gross profit rose 20% to $830.0 million, and Dexcom ended the quarter with $1.95 billion in cash, cash equivalents and short-term marketable securities.
- Selling, general and administrative expense rose 9%, including $12.1 million in additional advertising and marketing costs and $6.7 million in higher compensation costs.
- Gross margin gains were partly offset by higher excess and obsolete inventory charges tied to the planned discontinuation of G6 manufacturing.
- The effective tax rate declined, partly because of the start of a Malaysia tax holiday.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2 - MANAGEMENT’S DISCUSSION Overview Who We Are We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.